Staphylococcus aureus bacteremia in Danish patients with cardiac implantable electronic devices: an explorative epidemiological study

Abstract Background Device-related infection is the most common serious complication in patients with cardiac implantable electronic devices (CIED). Staphylococcus aureus accounts for up to 30% of CIED-related infections. There a lack scientific literature investigating risk bacteremia (SAB) CIED-patients. Purpose We aimed describe SAB Danish CIED through years 2000–2018 compared background population. Methods Patients who received from were identified The National Pacemaker and ICD Register. matched 1:5 on age gender primary endpoint first time Aureus Bacteremia Database. cumulative incidence was calculated using Aalen-Johansen estimator, adding competing death into account. Hazard ratios estimated by Cox regression models adjusting gender. Crude rates relapse SAB, defined as new episode 14–180 days after device extractions reported all survived 14 diagnosis. Results 79,324 CIED-patients (pacemaker (PM) = 61,227; Implantable Cardioverter Defibrillator (ICD) 11,635; Cardiac resynchronization therapy, PM or (CRT) 6,364 396,590 controls (median 75.5±13.3 years; 61% males). Age distribution differed significantly type (age: 76.1±12.1; 62.4±13.4; CRT 68.0±11.1; males: PM: 55.6%, ICD% 75.5: CRT: 80.9%). Across mean follow-up 5.9 (±4.6) years, we observed 1,430 (1.8%) CIED-patients, 2,599 (0.7%) control population (p<0.001). 10-year 1.0% 2.2% patients. substantially (Figure 1). Compared adjusted gender, increasing hazard more advanced devices: 1.12 (1.11–1.13); 1.36 (1.33–1.39); 1.55 (1.51–1.59). However, did not have higher 30-day mortality than non-CIED (Controls 34.8%; 35.1%; 28.1% 26.1%, p=0.016). Out diagnosis (Controls=1,672; CIED=1,107), occurred 52 (3.1%) 51 (4.6%) (PM 4.0%; 5.8%; 6.3%). Device extraction within 30 undertaken less (PM: 11.3/13.6%; ICD: 22.7/27.5%; 17.4/20.1%). Conclusion occurrence increased devices. no difference between controls. Relapse 7%, despite low percentage early extractions. Funding Acknowledgement Type funding sources: None.